North East and North Cumbria
ICS Formulary
ICS Formulary
10 Musculoskeletal and joint diseases
10-01-04 Long-term control of gout
| Allopurinol |
|
First Choice
|
An allopurinol 100mg in 5ml suspension ( Do not prescribe allopurinol 200mg tablets, see separate entry below. |
|
unlicensed) is also approved for use. 
| Febuxostat Adenuric® |
|
Formulary
|
Approved for patients where allopurinol is not tolerated or contraindicated in line with NICE. |
 MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease (May 2023) NICE NG219: Gout: diagnosis and management |
|
|
Links
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
- MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease (May 2023)
- NICE NG100: Rheumatoid arthritis in adults: management
- NICE NG219: Gout: diagnosis and management
- NICE NG226: Osteoarthritis in over 16s: diagnosis and management
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence